Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38055246.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2872 and PMC identifier 10841601.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Acquired mutations in BTK, PLCG2, and BCL2 are associated with resistance to continuous targeted agent therapy in chronic lymphocytic leukemia (CLL). Here, we discuss new evidence that limiting the duration of CLL therapy may prevent the evolution of such resistance mutations, potentially facilitating effective retreatment strategies. See related article by Jain et al., p. 498.
Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell
- Antineoplastic Agents